Mark James Litton - President and CEO, Director at Athira Pharma, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
President and CEO, Director
Stock Symbol
ATHA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
All Insider Reports
All Insider Reports

Mark James Litton - trading volume in the past year for Athira Pharma, Inc.

Holdings reported by Mark James Litton for Athira Pharma, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Restricted Stock Units 108K $125K $0.56 Jun 30, 2025 Direct Common Stock
Common Stock 326K $95.6K $0.29 Jul 1, 2025 Direct
Common Stock 6.56K $1.64K $0.25 Jun 30, 2025 By Irrevocable Trust of OSL
Common Stock 6.56K $1.64K $0.25 Jun 30, 2025 By Irrevocable Trust of SWL
Common Stock 6.56K $1.64K $0.25 Jun 30, 2025 By Irrevocable Trust of WGL
Stock Option (Right to Buy) 334K Mar 3, 2025 Direct Common Stock

Transactions reported by Mark James Litton for Athira Pharma, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.